MAPK3 and type 2 diabetes mellitus: On the other hand, our findings showed that HSVSMCs from neither non-diabetic T2DM (Figure 5A) nor T2DM patients (Figure 5C) had any significant changes in the amounts of mROS generation following stimulation of the MAPK/ERK1,2 pathway with Ang II.